| Purpose:As a threat to the health of women, breast cancer which is one of the most common malignant tumor,attract more and more worldwide attention. It is the leading cause of death due to cancer for American women, whose incidence is keeping rising these years here in China.Breast cancer is a complicated disease involving multiple systems, therefore it calls for multiple disciplinary treatment such as surgery, chemotherapy, radiotherapy, endocrine therapy and treatment of Traditional Chinese Medicine. Options of adjuvant radiotherapy after modified radical mastectomy and the therapeutic effect when combined with Kanglaite injection in patients with postoperative bone metastasis are described in this article.Material and method: 1.20 patients after modified radical mastectomy are chosen, involving 10 cases of left breast cancer and 10 cases of right breast cancer. Both TOMO therapy and IMRT therapy are planed for each patient with total doses of 50Gy/25 f. It is assuring that 95% of the target volume meets the requirements of prescription dose. Differences of TOMO therapy and IMRT therapy are demonstrated by comparing the homogeneity, conformity of the two radiotherapy options and the doses that distributed in the organs at risk, such as heart, lung, sternum as well as the healthy side of breast. 2.To investigate the therapeutic effect of Kanglaite injection combined with TOMO therapy in the treatment of bone metastases in breast cancer, 62 breast cancer patients with bone metastasis were randomized into experimental group and control group. The experimental group is treated with Kanglaite injection combined with TOMO therapy, while the control group is treated with TOMO therapy only. Quality of life, relief of cancer pain and adverse reactions are assessed when the therapy is finished.Results:1.From the aspect of dosimetric analysis in postoperativeradiotherapy for left breast cancer, TOMO therapy excels in both conformity(CI)and homogeneity(HI) compared with IMRT therapy. In view of the lung, TOMO shows a lower dose distribution in V5,V10,V20 and V30. About the heart dose delivery,TOMO shows a lower dose distribution in V5, V10, V20 and V30. Comparisons in contralateral breast and sternum show that TOMO therapy distribute less dose than that of IMRT. In the comparison of the right breast cancer,TOMO shows a better dose distribution than IMRT in the point of CI and HI in the planning target volume(PTV),and also of lung, heart, sternum and the contralateral breast. 2.The ratio of Quality of Life in experimental group is 83.9% while that of the control group is 61.3%; the ratio of Relief of Cancer Pain in experimental group is 93.5%,while that of the control group is 77.4%; to assess hematologic toxicity by analyzing WBC, the experimental group is observed a decrease of 38.7%while that of the control group is 67.7%; anorexia developing in experimental group is 32.3% while in control group is 64.5%.Have statistical significance.Conclusion:1.As the research shows, for both the patients choosing postoperative radiotherapy who are with left breast cancer and those who are with right breast cancer, TOMO therapy is advanced in conformity and homogeneity,can largely decreases the dose that distributed to the organs at risk, reduces the risk of adverse reactions and is of significant predominance in dosimetry.2.The investigation of the therapeutic effect of Kanglaite injection combined with TOMO therapy in the treatment of bone metastases in breast cancer shows that the therapeutic combined with Chinese patent medicine Kanglaite injection can better improve patients’ quality of life, relieve cancer pain as well as reduce the ratio of adverse reactions after radiotherapy, showing the applying of Kanglaite injection is practical in clinic.
|
PDF Full Text Request